Sign In

An official website of the United States government

U.S. Department of Health & Human Services

Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

COVID-19 Therapeutics Threshold Determinations by Jurisdiction

HHS/ASPR established threshold levels for ordering COVID-19 therapeutics available to each jurisdiction. The tables below are available for archival purposes only.

To find out how HHS/ASPR is currently bringing COVID-19 therapeutics to your state or territory, see COVID-19 Therapeutics Thresholds, Orders, and Replenishment by Jurisdiction.

COVID-19 Therapeutics Threshold Determinations

May 1, 2023 - November 26, 2023

Monthly Threshold Determinations* Paxlovid
(nirmatrelvir co-packaged with ritonavir;
standard and reduced dose)
Lagevrio
(molnupiravir)
Total
November 27, 2023 0 0
0
October 30 - November 26, 2023
2,452,230 0
2,452,230
October 2, 2023 - October 29, 2023
2,452,230 0
2,452,230
August 28 - October 1, 2023 2,452,230 195,299 2,647,529
July 31 - August 27, 2023 2,452,230 195,299 2,647,529
July 1 - July 30, 2023 2,452,230 195,299 2,647,529
June 1 - June 30, 2023 2,450,200 194,911 2,645,111
May 1 - May 31, 2023 2,450,200 194,911 2,645,111

*Starting May 2023, COVID-19 therapeutic threshold determinations were made on a monthly cadence. As of November 27, 2023, USG ended threshold determinations due to the transition of oral antivirals to commercial market. See the Sunsetting the U.S. Government COVID-19 Therapeutics Distribution Program for more information and a timeline of important dates.

Weekly COVID-19 Therapeutic Threshold Determinations January 30 - April 30, 2023

Weekly Threshold Determinations
January 30 - April 30, 2023
Paxlovid
(nirmatrelvir co-packaged with ritonavir;
standard and reduced dose)
Lagevrio
(molnupiravir)
Total
April 24 - April 30, 2023 612,165 48,604 660,769
April 17 - April 23, 2023 612,165 48,604 660,769
April 10 - April 16, 2023 612,165 48,604 660,769
April 3 - April 9, 2023 613,705 49,099 662,804
March 27 - April 2, 2023 612,165 48,604 660,769
March 20 - March 26, 2023 612,165 48,604 660,769
March 13 - March 19, 2023 612,165 48,604 660,769
March 6 - March 12, 2023 612,165 48,604 660,769
February 27 - March 5, 2023 613,705 49,099 662,804
February 20 - February 26, 2023 612,165 48,604 660,769
February 13 - February 19, 2023 612,165 48,604 660,769
February 6 - February 12, 2023 612,115 48,296 660,411
January 30 - February 5, 2023 613,655 48,791 662,446

Weekly COVID-19 Therapeutic Threshold Determinations September 5, 2022 - January 29, 2023

Paxlovid
(Standard and reduced dose)
Lagevrio
(molnupiravir)
Evusheld Total
January 23 - January 29, 2023 612,115 48,296 0 660,411
January 16 - January 22, 2023 612,115 48,296 0 660,411
January 9 - January 15, 2023 612,060 48,240 0 660,300
January 2 - January 8, 2023 613,580 48,735 204,096 866,411
December 26, 2022 - January 1, 2023 612,060 48,240 0 660,300
December 19 - December 25, 2022 612,060 48,240 0 660,300
December 12 - December 18, 2022 612,060 48,240 0 660,300
December 5 - December 11, 2022 613,580 48,735 204,096 866,411
November 28 - December 4, 2022 612,060 48,240 0 660,300
November 21 - November 27, 2022 612,060 48,240 0 660,300
November 14 - November 20, 2022 612,060 48,240 0 660,300
November 7 - November 13, 2022 612,060 48,240 0 660,300
October 31 - November 6, 2022 613,580 48,735 204,096 866,411
October 24 - October 30, 2022 612,060 48,240 0 660,300
October 17 - October 23, 2022 612,060 48,240 0 660,300
October 10 - October 16, 2022 612,060 48,240 0 660,300
October 3 - October 9, 2022 613,580 48,735 204,096 866,411
September 26 - October 2, 2022 612,060 48,312 0 660,372
September 19 - September 25, 2022 612,060 91,920 0 703,980
September 12 - September 18, 2022 612,060 91,920 0 703,980
September 5 - September 11, 2022 612,060 91,920 0 703,980

Weekly COVID-19 Therapeutic Threshold Determinations April 25, 2022 – September 6, 2022

Paxlovid
(Standard and Renal)
Lagevrio
(molnupiravir)
Bebtelovimab Evusheld Total
September 6, 2022: Bebtelovimab Final Allocation - - 19,500 - 19,500
August 29-September 4, 2022 613,580 92,352 0 203,736 909,668
August 22-August 28, 2022 612,060 91,920 21,915 0 725,895
August 15-August 21, 2022 612,060 91,920 29,060 0 733,040
August 8-August 14, 2022 612,060 91,896 29,110 0 733,066
August 1-August 7, 2022 612,260 92,328 29,760 203,760 938,108
July 25-July 31, 2022 610,340 91,896 29,190 0 731,426
July 18-July 24, 2022 642,695 113,368 29,250 0 785,313
July 11-July 17, 2022 596,955 114,400 29,200 0 740,555
July 4-July 10, 2022 575,715 114,856 29,210 0 719,781
June 27-July 3, 2022 590,085 114,576 28,710 201,168 934,539
June 20-June 26, 2022 579,120 109,896 28,985 0 718,001
June 13-June 19, 2022 405,084 71,664 29,060 0 505,808
June 6-June 12, 2022 444,225 92,828 29,140 240 566,433
May 30-June 5, 2022 459,638 100,820 29,630 200,808 790,896
May 23-May 29, 2022 473,106 115,960 29,100 0 618,166
May 16-May 22, 2022 463,417 105,036 29,040 0 597,493
May 9-May 15, 2022 386,965
107,208 29,110 0 523,283
May 2-May 8, 2022 348,160 108,920 29,000 199,992 686,072
April 25-May 1, 2022 386,700 177,120 30,000 0 593,820

Prior COVID-19 Therapeutic Product Efforts

Date Range Threshold/Distribution/Allocation by Jurisdiction
September 13, 2021 - April 24, 2022 COVID-19 Therapeutics Distribution
November 9, 2020 - March 2, 2021 Bamlanivimab Distribution
November 24, 2020 - February 2, 2021 REGEN-COV Distribution
July 6, 2020 - October 4, 2020 Allocation of Commercial Veklury (Remdesivir) (PDF)
May 4, 2020 - June 29, 2020
Allocation of Donated Veklury (Remdesivir)